The COVID-19 crisis exposed just how fragile global supply routes can be. In early 2020, more than half of the U.S. stock of masks, gowns and gloves was sourced from a single region overseas, and export bans quickly choked the pipeline. A 2024 Government Accountability Office review warned that the nation still lacks a robust plan to prevent future medical-supply shortages (GAO Files).
Below are six evidence-based strategies hospital leaders can adopt—starting now—to hard-wire resilience into their PPE programs.
Domestic production shortens lead times, avoids export restrictions and meets stringent U.S. quality rules. In October 2024 the Biden Administration awarded up to $510 million to six U.S. firms to expand PPE manufacturing for the Strategic National Stockpile (Reuters).
Premier’s 2024 report likewise found that nearly 90 % of hospitals now rank domestic manufacturing as “important” or “very important” to their resiliency strategy (Premier).
GAO recommends that HHS—and, by extension, provider organizations—develop clear plans to mitigate medical-supply shortages, including holding buffer inventory for high-risk items (GAO Files).
Group-purchasing organizations (GPOs) can secure surge clauses, expedited shipping, and dual-source tiers that an individual hospital may not achieve alone. The American Hospital Association notes that eliminating product duplication and standardizing formularies across merged or affiliate facilities is critical to lower risk and cost (American Hospital Association).
Premier’s predictive AI tools now forecast shortages with 90 % accuracy and recommend clinically-approved substitutes (Premier). Pair technology with regular tabletop and full-scale drills:
Hospitals can tap federal programs for intelligence and funding:
Let’s build a stronger PPE safety net together. Contact USA MedPro’s clinical affairs team for sample policies, contract templates, and volume-pricing options.
